3 news items
Mustang Bio Expands CAR T-Cell Therapy Platform Expansion Into Autoimmune Diseases
MBIO
28 Mar 24
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
FBIO
MBIO
28 Mar 24
-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected
Mustang Bio Reports FY23 EPS Of $(6.00) Vs $(10.09) YoY And Recent Corporate Highlights
MBIO
11 Mar 24
Combined Immunodeficiency (XSCID):
In 2024, the first patients are expected to be treated in both new investigator
- Prev
- 1
- Next